Nevertheless, post hoc analysis of results from the CREDENCE trial (which studied the effects of canagliflozin on renal and cardiovascular outcomes in patients with diabetic nephropathy) and several other cardiovascular outcome trials using SGLT2 inhibitors have demonstrated benefits independent of their glucose-lowering capabilities [220,221]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.